9 A Pair Ranking (PRank) Method for Assessing Assay …
179
47. Ankley GT et al (2009) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29(3):730–741
48. Nymark P et al (2018) A data fusion pipeline for generating and enriching adverse outcome
pathway descriptions. Toxicol Sci 162(1):264–275
49. Bell SM et al (2016) Integrating publicly available data to generate computationally predicted
adverse outcome pathways for fatty liver. Toxicol Sci 150(2):510–520
50. Bal-Price A, Meek ME (2017) Adverse outcome pathways: application to enhance mechanistic
understanding of neurotoxicity. Pharmacol Ther 179:84–95
51. Perkins EJ et al (2015) Adverse outcome pathways for regulatory applications: examination of
four case studies with different degrees of completeness and scientific confidence. Toxicol Sci
148(1):14–25
52. Patlewicz G et al (2014) Food for thought: read-across approaches—misconceptions, promises
and challenges ahead. ALTEX-Altern Anim Experimentation 31(4):387–396
53. Zhu H et al (2016) t(4) report: supporting read-across using biological data. Altex
33(2):167–182
54. Subramanian A et al (2017) A next generation connectivity map: L1000 platform and the first
1,000,000 profiles. Cell 171(6):1437–1452.e1417
55. Koleti A et al (2018) Data portal for the library of integrated network-based cellular signatures
(LINCS) program: integrated access to diverse large-scale cellular perturbation response data.
Nucleic Acids Res 46(D1):D558–D566
Zhichao Liu got his Ph.D. from Nankai University in China. He is currently a principal investigator at NCTR, FDA. Dr. Liu’s background is across Chemistry, Biology and Computer Science. In past 15 years, he led and took part in many cutting-edge projects from both industry
and academia. Specifically, he developed innovative approaches for in silico drug repositioning
framework to seek for novel opportunities for rare disease treatment development. The goals aim
at providing the standard in silico pipeline for drug repositioning and early drug safety detection
by retrieving, integrating, and organizing the information from chemical, biological, and clinical
spaces, which help industry to seek for the optimal route to accelerate the drug development efficacy from advanced regulatory sciences perspective. His interests also widely cover (1) development of flexible and integrative risk prediction systems for drug safety evaluation; (2) development and application of standard pipeline for genomic data (e.g., microarray/NGS) analysis for
drug safety and efficacy questions. Dr. Liu has published more than 60 papers in the prestigious
journals.
Brian Delavan is a Ph.D. candidate in College of Public Health at University of Arkansas for
Medical Sciences. His research has focused on developing computational approaches for drug
repositioning of rare diseases and bio-imaging analysis. Brian received his Master of Public Health
(MPH) at University of Arkansas for Medical Sciences in 2016.
Liyuan Zhu graduated from Tsinghua University with a bachelor’s degree in Biology. After that,
he studied Molecular Virology and Microbiology at Baylor College of Medicine, where he discovered his interests in bioinformatics. He then got a master’s degree at Columbia University in
Biomedical Informatics. He now works at NCTR, FDA on toxicogenomics research.
Ruth Robert is chair of drug discovery at Birmingham University, UK and Cofounder of
ApconiX, an integrated toxicology and ion channel company that brings together a team of worldrenowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of
Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer-reviewed
179
47. Ankley GT et al (2009) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29(3):730–741
48. Nymark P et al (2018) A data fusion pipeline for generating and enriching adverse outcome
pathway descriptions. Toxicol Sci 162(1):264–275
49. Bell SM et al (2016) Integrating publicly available data to generate computationally predicted
adverse outcome pathways for fatty liver. Toxicol Sci 150(2):510–520
50. Bal-Price A, Meek ME (2017) Adverse outcome pathways: application to enhance mechanistic
understanding of neurotoxicity. Pharmacol Ther 179:84–95
51. Perkins EJ et al (2015) Adverse outcome pathways for regulatory applications: examination of
four case studies with different degrees of completeness and scientific confidence. Toxicol Sci
148(1):14–25
52. Patlewicz G et al (2014) Food for thought: read-across approaches—misconceptions, promises
and challenges ahead. ALTEX-Altern Anim Experimentation 31(4):387–396
53. Zhu H et al (2016) t(4) report: supporting read-across using biological data. Altex
33(2):167–182
54. Subramanian A et al (2017) A next generation connectivity map: L1000 platform and the first
1,000,000 profiles. Cell 171(6):1437–1452.e1417
55. Koleti A et al (2018) Data portal for the library of integrated network-based cellular signatures
(LINCS) program: integrated access to diverse large-scale cellular perturbation response data.
Nucleic Acids Res 46(D1):D558–D566
Zhichao Liu got his Ph.D. from Nankai University in China. He is currently a principal investigator at NCTR, FDA. Dr. Liu’s background is across Chemistry, Biology and Computer Science. In past 15 years, he led and took part in many cutting-edge projects from both industry
and academia. Specifically, he developed innovative approaches for in silico drug repositioning
framework to seek for novel opportunities for rare disease treatment development. The goals aim
at providing the standard in silico pipeline for drug repositioning and early drug safety detection
by retrieving, integrating, and organizing the information from chemical, biological, and clinical
spaces, which help industry to seek for the optimal route to accelerate the drug development efficacy from advanced regulatory sciences perspective. His interests also widely cover (1) development of flexible and integrative risk prediction systems for drug safety evaluation; (2) development and application of standard pipeline for genomic data (e.g., microarray/NGS) analysis for
drug safety and efficacy questions. Dr. Liu has published more than 60 papers in the prestigious
journals.
Brian Delavan is a Ph.D. candidate in College of Public Health at University of Arkansas for
Medical Sciences. His research has focused on developing computational approaches for drug
repositioning of rare diseases and bio-imaging analysis. Brian received his Master of Public Health
(MPH) at University of Arkansas for Medical Sciences in 2016.
Liyuan Zhu graduated from Tsinghua University with a bachelor’s degree in Biology. After that,
he studied Molecular Virology and Microbiology at Baylor College of Medicine, where he discovered his interests in bioinformatics. He then got a master’s degree at Columbia University in
Biomedical Informatics. He now works at NCTR, FDA on toxicogenomics research.
Ruth Robert is chair of drug discovery at Birmingham University, UK and Cofounder of
ApconiX, an integrated toxicology and ion channel company that brings together a team of worldrenowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of
Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer-reviewed